封面
市场调查报告书
商品编码
1577522

组织微阵列的全球市场

Tissue Microarrays

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年,美国全球组织微阵列市场将达到 141 亿美元

全球组织微阵列市场预计 2023 年为 91 亿美元,预计到 2030 年将达到 141 亿美元,2023 年至 2030 年复合年增长率为 6.5%。免疫组织化学程序是本报告分析的细分市场之一,复合年增长率为 7.2%,预计到分析期结束时将达到 65 亿美元。在分析期间,萤光原位杂合技术(FISH) 部分的复合年增长率估计为 6.6%。

美国市场预计24亿美元,中国预计复合年增长率6.3%

到 2023 年,美国组织微阵列市场预计将达到 24 亿美元。中国作为世界第二大经济体,预计2030年市场规模将达23亿美元,2023-2030年分析期间复合年增长率为6.3%。其他值得注意的区域市场包括日本和加拿大,在分析期间预计复合年增长率分别为 6.1% 和 5.5%。在欧洲,德国的复合年增长率预计为 5.2%。

全球组织微阵列市场-主要趋势与驱动因素总结

什么是组织微阵列以及它们如何促进生物医学研究?

组织微阵列 (TMA) 是强大的研究工具,可在单张玻片上同时分析多个组织样本。该技术可以有效检查通常从患者或实验模型中获得的各种组织,并有助于比较不同病例之间的病理差异、基因表现和蛋白质活性。 TMA 透过对组织样本进行大规模分析来帮助识别潜在的生物标记、检验诊断测试并评估标靶治疗的有效性,彻底改变了生物医学研究,特别是在肿瘤学领域。每个微阵列包含来自不同组织样本的数百个小型代表性核心,使研究人员能够同时对多个样本进行免疫组织化学 (IHC) 和原位杂合反应(ISH) 等实验,并节省大量时间和资源。

技术创新如何形塑组织微阵列市场?

技术进步促进了组织微阵列的功能和准确性的显着改进。自动化 TMA 建置工具的引入可以实现更准确和可重复的阵列创建,减少组织核心之间的变异性并确保更好的实验可靠性。此外,数位病理学和成像技术的进步使得更有效地分析 TMA 成为可能。高解析度扫描系统和基于人工智慧的影像分析工具使研究人员能够更快、更精确地量化和评估组织标记。此外,多重免疫组织化学的效用以及从单一组织核心同时检测多种蛋白质和遗传标记的能力使得复杂的研究环境成为可能,例如癌症生物学,其中多因素资料非常重要。

哪些产业和医疗保健趋势将影响组织微阵列?

组织微阵列由于其在转化研究和个人化医疗中的重要作用而受到医疗保健和製药行业的关注。随着对精准治疗开发的重视,特别是在肿瘤学领域,TMA 提供了一个有效的平台来识别特定的生物标记以指南治疗决策。在药物发现中,TMA 用于评估不同药物如何影响不同的组织类型,从而可以更快地筛检,并在开发新治疗方法时获得更多信息,从而能够做出决策。此外,对更强大、更可靠的诊断工具的需求不断增长,推动了 TMA 在检验各种疾病的诊断测试中的使用。学术和研究机构越来越多地转向大规模、资料驱动的研究,将 TMA 定位为癌症、心血管和神经退化性疾病研究中高通量分析的宝贵工具。

推动组织微阵列市场成长的因素有哪些?

组织微阵列市场的成长受到多种因素的推动。自动化阵列建构和数位病理学方面的技术进步使 TMA 更容易获得和高效,从而增加了其在研究和临床实践中的采用。对个人化医疗的需求不断增长,特别是在肿瘤学领域,显着促进了 TMA 在生物标记发现和标靶治疗检验中的使用。製药公司越来越多地利用 TMA 来简化药物开发流程,并减少与评估潜在治疗方法相关的时间和成本。此外,人们越来越关注开发针对慢性和复杂疾病的可靠诊断方法,增加了测试验证和比较病理学研究中对 TMA 的需求。为研究提供高品质组织样本的组织库和生物样本库的扩张进一步推动了 TMA 市场的成长。最后,政府对癌症研究和大规模生物医学研究的津贴不断增加,正在推动世界各地学术和研究机构采用 TMA。

调查企业范例(共42例)

  • 3DHISTECH Ltd.
  • Array Science, LLC
  • Bio Sb
  • Cureline, Inc.
  • Indica Labs, Inc.
  • Innopsys France
  • Mopec, Inc.
  • Novus Biologicals LLC
  • OracleBio
  • OriGene Technologies, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP24412

Global Tissue Microarrays Market to Reach US$14.1 Billion by 2030

The global market for Tissue Microarrays estimated at US$9.1 Billion in the year 2023, is expected to reach US$14.1 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2023-2030. Immunohistochemistry Procedure, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$6.5 Billion by the end of the analysis period. Growth in the Fluorescence In-Situ Hybridization (FISH) Procedure segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 6.3% CAGR

The Tissue Microarrays market in the U.S. is estimated at US$2.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.1% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Tissue Microarrays Market – Key Trends & Drivers Summarized

What Are Tissue Microarrays and How Do They Advance Biomedical Research?

Tissue microarrays (TMAs) are a powerful research tool used to analyze multiple tissue samples simultaneously on a single slide. This technique allows for the efficient examination of a wide variety of tissues, typically sourced from patients or experimental models, making it easier to compare pathological differences, gene expressions, or protein activity across different cases. TMAs have revolutionized biomedical research, particularly in oncology, by enabling the large-scale analysis of tissue samples, which helps identify potential biomarkers, validate diagnostic tests, and assess the efficacy of targeted therapies. Each microarray contains hundreds of tiny, representative cores from different tissue samples, allowing researchers to run experiments like immunohistochemistry (IHC) or in situ hybridization (ISH) on multiple samples at once, significantly saving time and resources compared to traditional methods.

How Are Technological Innovations Shaping the Tissue Microarrays Market?

Technological advancements are driving significant improvements in the functionality and accuracy of tissue microarrays. The introduction of automated TMA construction tools has enabled more precise and reproducible array creation, reducing the variability between tissue cores and ensuring better experimental reliability. Additionally, advancements in digital pathology and imaging technologies have made it possible to analyze TMAs more effectively. High-resolution scanning systems and AI-based image analysis tools allow researchers to quantify and assess tissue markers more quickly and with greater accuracy. Furthermore, innovations in multiplexed immunohistochemistry and the ability to simultaneously detect multiple proteins or genetic markers within a single tissue core are further expanding the utility of tissue microarrays in complex research settings like cancer biology, where multifactorial data is crucial.

What Industry and Healthcare Trends Are Influencing Tissue Microarrays?

In the healthcare and pharmaceutical industries, tissue microarrays are gaining traction due to their critical role in translational research and personalized medicine. With the growing emphasis on developing precision therapies, especially in oncology, TMAs offer an effective platform for identifying specific biomarkers that can guide treatment decisions. In pharmaceutical drug discovery, TMAs are used to evaluate how different drugs impact various tissue types, enabling quicker screening and more informed decision-making in the development of new therapies. Additionally, the increasing demand for more robust and reliable diagnostic tools has encouraged the use of TMAs in validating diagnostic tests for various diseases. In academia and research institutions, the growing trend toward large-scale, data-driven research has positioned tissue microarrays as a valuable tool for conducting high-throughput analyses in studies related to cancer, cardiovascular diseases, and neurodegenerative conditions.

What Factors Are Driving Growth in the Tissue Microarrays Market?

The growth in the tissue microarrays market is driven by several factors. Technological advancements in automated array construction and digital pathology are making TMAs more accessible and efficient, thereby increasing their adoption in research and clinical settings. The rising demand for personalized medicine, particularly in oncology, is significantly boosting the use of TMAs for biomarker discovery and targeted therapy validation. Pharmaceutical companies are increasingly utilizing TMAs to streamline drug development processes, reducing the time and costs associated with evaluating potential treatments. Additionally, the growing focus on developing robust diagnostics for chronic and complex diseases is propelling the need for TMAs in test validation and comparative pathology studies. The expansion of tissue banks and biorepositories, which provide high-quality tissue samples for research, is further supporting the growth of the TMA market. Lastly, increased government funding for cancer research and large-scale biomedical studies is driving the adoption of TMAs in academic and research institutions around the world.

Select Competitors (Total 42 Featured) -

  • 3DHISTECH Ltd.
  • Array Science, LLC
  • Bio Sb
  • Cureline, Inc.
  • Indica Labs, Inc.
  • Innopsys France
  • Mopec, Inc.
  • Novus Biologicals LLC
  • OracleBio
  • OriGene Technologies, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Tissue Microarrays - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for High-Throughput Tissue Analysis Propels Growth in the Tissue Microarrays Market
    • Increasing Use of Tissue Microarrays in Cancer Research Expands Addressable Market for Diagnostic and Therapeutic Applications
    • Advancements in Immunohistochemistry (IHC) and In Situ Hybridization (ISH) Technologies Strengthen Business Case for Tissue Microarrays
    • Growing Need for Efficient Biomarker Validation in Personalized Medicine Drives Adoption of Tissue Microarrays
    • Technological Innovations in Multiplexing Techniques Accelerate the Use of Tissue Microarrays in Research and Diagnostics
    • Increasing Focus on Precision Oncology Generates Opportunities for Tissue Microarrays in Tumor Analysis
    • Rising Investment in Translational Research Expands the Market for Tissue Microarrays in Clinical Trials
    • Increasing Prevalence of Chronic Diseases and Cancer Fuels Demand for Tissue Microarrays in Pathology
    • Growing Applications of Tissue Microarrays in Drug Development Strengthens Market for Pharmaceutical Research
    • Expansion of Tissue Banks and Biorepositories Supports Growth of the Tissue Microarrays Market
    • Rising Use of Tissue Microarrays in Immunotherapy Research and Development Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tissue Microarrays Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tissue Microarrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tissue Microarrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Tissue Microarrays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunohistochemistry Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunohistochemistry Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Immunohistochemistry Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Fluorescence In-Situ Hybridization (FISH) Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Fluorescence In-Situ Hybridization (FISH) Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Fluorescence In-Situ Hybridization (FISH) Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for In Situ Hybridization Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for In Situ Hybridization Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for In Situ Hybridization Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Procedures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Tissue Microarrays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Tissue Microarrays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Tissue Microarrays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION